Maximus, MD-Led Platform

Maximus is a men's health telehealth company built around a clinical thesis that distinguishes it from the majority of the online TRT market: not every man with suboptimal testosterone needs exogenous testosterone. The company's flagship protocol — enclomiphene-only therapy — uses a selective estrogen receptor modulator to stimulate the pituitary gland to produce more LH and FSH, which in turn signals the testes to increase their own testosterone production. The result, in appropriate candidates, is higher endogenous testosterone without the testicular suppression, fertility impact, or lifelong dependency associated with exogenous testosterone replacement. This therapeutic philosophy is clinically meaningful in a market where injectable testosterone is often the first and only option offered, regardless of patient age, fertility intentions, or whether the hypothalamic-pituitary-gonadal axis is functional. For men in their 30s with borderline testosterone who want to maintain fertility — or who are not yet ready to commit to TRT — enclomiphene represents a clinically validated alternative that most online TRT platforms simply do not offer. Maximus has built its brand identity partly around this differentiation: while competitors compete primarily on price and convenience for testosterone injections, Maximus positions itself as the more nuanced clinical choice. The platform is entirely digital. After an at-home lab test (finger-prick or venous sample), a board-certified physician reviews the results and prescribes from a menu that includes enclomiphene alone, testosterone cream or oral testosterone, injectable testosterone cypionate, and combination protocols that pair testosterone with enclomiphene or hCG to maintain testicular function and fertility. Protocols are priced by complexity, starting at $99.99/month for single-agent therapy and scaling to $299.99/month for advanced combination protocols. A Building Blocks multivitamin formulated for men on hormone therapy is available as an add-on. Physician access is asynchronous — members communicate with their board-certified doctor via 24/7 in-app messaging rather than scheduled video calls, which suits the platform's self-directed patient demographic. For men who want to ask detailed questions about protocol design, peptide additions, or laboratory result interpretation, this model works well; for patients who need significant hand-holding or clinical reassurance, a more concierge-oriented platform may serve them better. Maximus serves patients nationwide without in-person requirements, operating fully within the current telemedicine regulatory framework. The company has continued to expand its protocol menu since launch and has developed a strong following among men who approach hormone optimization as a research-informed, self-directed practice. The company's flagship protocol — enclomiphene-only therapy — uses a selective estrogen receptor modulator to stimulate the pituitary gland to produce more LH and FSH, which in turn signals the testes to increase their own testosterone production. The result, in appropriate candidates, is higher endogenous testosterone without the testicular suppression, fertility impact, or lifelong dependency associated with exogenous testosterone replacement. This therapeutic philosophy is clinically meaningful in a market where injectable testosterone is often the first and only option offered, regardless of patient age, fertility intentions, or whether the hypothalamic-pituitary-gonadal axis is functional. For men in their 30s with borderline testosterone who want to maintain fertility — or who are not yet ready to commit to TRT — enclomiphene represents a clinically validated alternative that most online TRT platforms simply do not offer. Maximus has built its brand identity partly around this differentiation: while competitors compete primarily on price and convenience for testosterone injections, Maximus positions itself as the more nuanced clinical choice. The platform is entirely digital. After an at-home lab test (finger-prick or venous sample), a board-certified physician reviews the results and prescribes from a menu that includes enclomiphene alone, testosterone cream or oral testosterone, injectable testosterone cypionate, and combination protocols that pair testosterone with enclomiphene or hCG to maintain testicular function and fertility. Protocols are priced by complexity, starting at $99.99/month for single-agent therapy and scaling to $299.99/month for advanced combination protocols. A Building Blocks multivitamin formulated for men on hormone therapy is available as an add-on. Physician access is asynchronous — members communicate with their board-certified doctor via 24/7 in-app messaging rather than scheduled video calls, which suits the platform's self-directed patient demographic. For men who want to ask detailed questions about protocol design, peptide additions, or laboratory result interpretation, this model works well; for patients who need significant hand-holding or clinical reassurance, a more concierge-oriented platform may serve them better. Maximus serves patients nationwide without in-person requirements, operating fully within the current telemedicine regulatory framework. The company has continued to expand its protocol menu since launch and has developed a strong following among men who approach hormone optimization as a research-informed, self-directed practice.